



## Epigenomics in Prostate Cancer

Guest Editor:

### Dr. Antoinette S. Perry

Cancer Biology and Therapeutics  
Laboratory, UCD Conway  
Institute of Biomolecular and  
Biomedical Research, University  
College Dublin, Dublin, Ireland  
School of Biology and  
Environmental Science,  
University College Dublin, Dublin,  
Ireland

Deadline for manuscript  
submissions:

**closed (31 May 2021)**

### Message from the Guest Editor

Dear Colleagues,

Prostate cancer is one of the most common male malignancies in the world. It displays a high incidence to mortality ratio, meaning that the majority of men experience a relatively low-risk, latent form of the disease. However, a proportion of tumours have an aggressive nature and hence prostate cancer is the 5th leading cause of cancer-related deaths in men worldwide. The fact that prostate cancer displays an atypically low mutation rate, has undoubtedly contributed to our lack of clarity on hallmark molecular features of aggressive and indolent disease. By contrast, epigenetic alterations are frequent during prostate cancer initiation and progression and indeed the disease is known to undergo an epigenetic catastrophe during the earliest stages of tumour development, with widespread promoter hypermethylation and silencing of regulatory genes.

This special issue will highlight the central, yet complex, role that epigenomics plays in prostate cancer, from disease development through to castration resistance, and the utility that it offers in disease detection, stratification and prognostication.

Dr. Antoinette S. Perry  
Guest Editor





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)